EN DE
Watch CHO Pharma Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CHO Pharma Inc. (6586) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of CHO Pharma Inc. stock TWD 29.50, price TWD 74.40, that is 60.3% below the price, quality 30 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

CP CHO Pharma Inc. logo Thin data Nov 10, 2026

CHO Pharma Inc.

6586 · TWO
Very expensive, weak quality

Our calculation puts a fair price 60% below what the stock costs today.

Revenue last quarter +39% vs. a year ago.
Mixed Growth (revenue 5y +59.6 %/yr in TWD)
Mixed vs. peers (3/6)
Fair value 29.50 TWD · Strongly overvalued
Quality 30/100
Negative free cash flow
Narrow moat 10/100
Thin data
Estimate
Watch CHO Pharma Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

237.00 TWD 23.35 TWD Fair Value 29.50 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 23.35 TWD – 237.00 TWD · fair‑value band 22.13 TWD – 36.88 TWD · the 74.40 TWD price screens above the 29.50 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow CHO Pharma in your weekly email

Every Wednesday you see whether CHO Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan.

Show moreShow less

It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies.

The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which is in Phase I/IIa clinical trials for the treatment of refractory non-Hodgkin lymphoma; CHO-A04, a humanized monoclonal antibody, which is in phase I clinical trials to treat various tumor and cancer stem cells; and CHO-V08 vaccines for the treatment of klebsiella pneumonia.

Further, it develops CHO-H02 that is in preclinical stage to target solid tumors, including breast, bladder, pancreatic, ovarian, and gastric cancers; and CHO-H03, an antibody drug that is in pre-clinical development stage indicated for inflammatory conditions in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and Crohn's disease.

CHO Pharma, Inc. was founded in 2012 and is based in Taipei City, Taiwan.

Stock analysis

CHO Pharma Inc. (6586) currently trades at 74.40 TWD, while our estimate is 29.50 TWD, 60% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 22.13 TWD (bear) to 36.88 TWD (bull), the price of 74.40 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

CHO Pharma Inc. reported revenue of 1.4M TWD in FY2025 versus 3.6M TWD in FY2021, a compound −20.4%/yr. Reported net income was −290M TWD in FY2025.

Key figures

Market cap 21.6B TWD (≈ $658M) Small · EPS (TTM) −1.26 TWD · Return on equity −10.7% · Return on assets (EBIT) −12.6% (5-year average) · Operating margin −11,417% · Revenue (TTM) 1.7M TWD · Revenue growth (YoY) +38.5% · Free cash flow −291M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (medium confidence).

What moves the price

The share trades about 45% below its 52-week high and 219% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −60%, 6586 screens richer than that median.

Fair Value

Bear 22.13 TWD Fair Value 29.50 TWD Bull 36.88 TWD
Price 74.40 TWD · Downside -60.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 32
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 5
Does it invest with discipline instead of growing at any price?
Low Volatility 33
How calm the share price moves, does not count
Price momentum 59
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 73
Distance to the 52-week high, does not count
New shares 55
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 22/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−60.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+187.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+59.6%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−214,539.1% (2020) → −22,770.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6586 screens overvalued: fair value 60% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CHO Pharma Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −60.3% · Bottom 25%
Profitability
Return on assets −11.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) 38.5% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.77× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 6586
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 6586
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 6586
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 6586
argenx SE ARGX $971.55 $908.40 −7% vs 6586
CSL Limited CSL A$201.68 A$181.40 −10% vs 6586
Moderna, Inc MRNA $250.83 $158.70 −37% vs 6586
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 6586
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 6586
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 6586

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CHO Pharma Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CHO Pharma Inc. Fair Value". https://www.fairvalue-calculator.com/stock/6586

Frequently asked questions

Is CHO Pharma Inc. (6586) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 29.50 TWD versus a price of 74.40 TWD, about 60% lower (overvalued).
What is the fair value of 6586?
Our estimate for CHO Pharma Inc. is 29.50 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 74.40 TWD.
What is the quality score of 6586?
CHO Pharma Inc. has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CHO Pharma Inc. (6586)?
Our calculated price target is the estimate of 29.50 TWD (as of Nov 10, 2026). Cautious scenario 22.13 TWD, optimistic scenario 36.88 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CHO Pharma Inc. stock forecast for 2026?
Our estimate puts fair value at 29.50 TWD, about 60% lower versus a price of 74.40 TWD (overvalued). Cautious scenario 22.13 TWD, optimistic scenario 36.88 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of CHO Pharma Inc. (6586)?
CHO Pharma Inc. reported trailing-twelve-month revenue of about 1.7M TWD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of CHO Pharma Inc. (6586)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CHO Pharma Inc. it is 29.50 TWD per share (as of Nov 10, 2026), against a price of 74.40 TWD.
Is CHO Pharma Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 6586 trades above its calculated fair value: price 74.40 TWD, fair value 29.50 TWD, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6586?
No. The price is what the market pays today (74.40 TWD); the fair value is what the company's own numbers justify (29.50 TWD). For CHO Pharma Inc. the two are 44.90 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is CHO Pharma Inc. worth?
The market values CHO Pharma Inc. at about 21.6B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 74.40 TWD; our models calculate a fair value of 29.50 TWD per share.
What do the bullish and bearish scenarios say about 6586?
Our models span a range for CHO Pharma Inc.: cautious scenario 22.13 TWD, base 29.50 TWD, optimistic 36.88 TWD per share (as of Nov 10, 2026, price 74.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CHO Pharma Inc. (6586)?
Balance-sheet figures for CHO Pharma Inc. (as of Nov 10, 2026): return on equity −10.7%. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is 6586 from its 52-week high?
CHO Pharma Inc. trades at 74.40 TWD, about 45% below its 52-week high of 135.50 TWD and 219% above the low of 23.35 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 29.50 TWD is for.
Which stocks are comparable to CHO Pharma Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CHO Pharma Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price 74.40 TWD, calculated fair value 29.50 TWD (−60%), Quality Score 30/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. CHO Pharma Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CHO Pharma Inc. (6586)?
The closing price on Nov 10, 2026 was 74.40 TWD. Our estimate is 29.50 TWD, about 60% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CHO Pharma Inc. right now?
The price sits above even our optimistic bull case (36.88 TWD). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CHO Pharma Inc.

How large is the market capitalisation of CHO Pharma Inc. (6586)?
The market capitalisation of CHO Pharma Inc. is 21.6B TWD (≈ $658M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of CHO Pharma Inc. (6586)?
Earnings per share at CHO Pharma Inc. are −1.26 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CHO Pharma Inc. (6586)?
The return on equity (ROE) of CHO Pharma Inc. is −10.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CHO Pharma Inc. (6586)?
On an EBIT basis the return on assets of CHO Pharma Inc. is −12.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CHO Pharma Inc. (6586)?
The operating margin of CHO Pharma Inc. is −11,417% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CHO Pharma Inc. (6586)?
Revenue at CHO Pharma Inc. is growing +38.5% versus a year earlier (3y avg +188%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CHO Pharma Inc. (6586) generate?
The free cash flow of CHO Pharma Inc. is −291M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CHO Pharma Inc. (6586) hold?
CHO Pharma Inc. holds more cash than debt, 204M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CHO Pharma Inc. in the live analysis

One click puts CHO Pharma Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.